Searched for: school:SOM
Department/Unit:Population Health
Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
Mulder, Renée L; Font-Gonzalez, Anna; van Dulmen-den Broeder, Eline; Quinn, Gwendolyn P; Ginsberg, Jill P; Loeffen, Erik A H; Hudson, Melissa M; Burns, Karen C; van Santen, Hanneke M; Berger, Claire; Diesch, Tamara; Dirksen, Uta; Giwercman, Aleksander; Gracia, Clarisa; Hunter, Sarah E; Kelvin, Joanne F; Klosky, James L; Laven, Joop S E; Lockart, Barbara A; Neggers, Sebastian J C M M; Peate, Michelle; Phillips, Bob; Reed, Damon R; Tinner, Eva Maria E; Byrne, Julianne; Veening, Margreet; van de Berg, Marleen; Verhaak, Chris M; Anazodo, Antoinette; Rodriguez-Wallberg, Kenny; van den Heuvel-Eibrink, Marry M; Asogwa, Ogechukwu A; Brownsdon, Alexandra; Wallace, W Hamish; Green, Daniel M; Skinner, Roderick; Haupt, Riccardo; Kenney, Lisa B; Levine, Jennifer; van de Wetering, Marianne D; Tissing, Wim J E; Paul, Norbert W; Kremer, Leontien C M; Inthorn, Julia
Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.
PMID: 33539755
ISSN: 1474-5488
CID: 4799042
Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
Mulder, Renée L; Font-Gonzalez, Anna; Hudson, Melissa M; van Santen, Hanneke M; Loeffen, Erik A H; Burns, Karen C; Quinn, Gwendolyn P; van Dulmen-den Broeder, Eline; Byrne, Julianne; Haupt, Riccardo; Wallace, W Hamish; van den Heuvel-Eibrink, Marry M; Anazodo, Antoinette; Anderson, Richard A; Barnbrock, Anke; Beck, Joern D; Bos, Annelies M E; Demeestere, Isabelle; Denzer, Christian; Di Iorgi, Natascia; Hoefgen, Holly R; Kebudi, Rejin; Lambalk, Cornelis; Langer, Thorsten; Meacham, Lillian R; Rodriguez-Wallberg, Kenny; Stern, Catharyn; Stutz-Grunder, Eveline; van Dorp, Wendy; Veening, Margreet; Veldkamp, Saskia; van der Meulen, Eline; Constine, Louis S; Kenney, Lisa B; van de Wetering, Marianne D; Kremer, Leontien C M; Levine, Jennifer; Tissing, Wim J E
Female patients with childhood, adolescent, and young adult cancer are at increased risk for fertility impairment when treatment adversely affects the function of reproductive organs. Patients and their families desire biological children but substantial variations in clinical practice guidelines reduce consistent and timely implementation of effective interventions for fertility preservation across institutions. As part of the PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. This clinical practice guideline leverages existing evidence and international expertise to develop transparent recommendations that are easy to use to facilitate the care of female patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment. A complete review of the existing evidence, including a quality assessment, transparent reporting of the guideline panel's decisions, and achievement of global interdisciplinary consensus, is an important result of this intensive collaboration.
PMID: 33539753
ISSN: 1474-5488
CID: 4799032
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb, Stacy; Giri, Veda N
CONTEXT/BACKGROUND:Germline testing (GT) is increasingly impacting prostate cancer (PCa) management and screening, with direct effects in urology, medical oncology, and radiation oncology. The majority of testing indications and recommendations center on men with metastatic disease, although guidelines now encompass newly diagnosed, early-stage PCa and entail assessment of personal history, pathologic features, and family history to determine eligibility for testing. OBJECTIVE:To describe current guidelines on GT for men with PCa and the impact on management. An additional objective was to review the literature on current uptake of GT across practice settings. EVIDENCE ACQUISITION/METHODS:A nonsystematic review was performed of current guidelines on GT in PCa from professional societies and consensus conferences, detailing supporting evidence for these recommendations. This was supplemented by a literature review of uptake of GT and precision medicine in practice. EVIDENCE SYNTHESIS/RESULTS:Multiple guidelines and consensus panels recommend GT for men with metastatic PCa. Guidelines endorse BRCA2 testing in metastatic PCa because of strong evidence for PCa risk, aggressiveness, and PARP inhibitor candidacy. Testing of additional DNA repair genes in metastatic disease is also endorsed across guidelines. Immunotherapy with pembrolizumab is an option in some guidelines for men with DNA mismatch repair deficiency. In localized disease, GT is recommended on the basis of histologic features and family history; criteria vary between guidelines. GT for localized disease informs hereditary cancer risk and will probably impact future PCa management. Practice gaps exist regarding utilization of GT. CONCLUSIONS:Germline evaluation is increasingly important in the management of men with metastatic PCa and may also affect the prognosis for men with localized disease. The presence of germline mutations has important hereditary cancer implications for men and their families. Uptake of germline evaluation may be underutilized in some practice settings, so strategies for optimization are required. PATIENT SUMMARY/UNASSIGNED:Patients with prostate cancer should talk to their doctor about the pros and cons of genetic testing, with attention to family history and cancer features. Genetic testing can have important implications for treatment, cancer screening, and family cancer risk.
PMID: 33390340
ISSN: 2588-9311
CID: 4759262
Executive Function and BMI Trajectories Among Rural, Poor Youth at High Risk for Obesity
Rollins, Brandi Y; Riggs, Nathaniel R; Francis, Lori A; Blair, Clancy B
OBJECTIVE:The aim of this study was to identify longitudinal trajectories of conjoint development of executive function (EF) and obesity among a diverse sample of poor, rural youth and to evaluate individual differences in infant growth, parental BMI, and cumulative risk. METHODS:Participants included 948 youth from the Family Life Project. Child anthropometrics were measured at 2 and 6 months and at 2, 3, 4, 5, 7, and 12 years. EF tasks were administered at 3, 4, and 5 years. Mothers reported youth birth weight, parental height and weight, and cumulative risk indicators. RESULTS:Multidimensional growth mixture modeling identified three classes: "High EF - High Obesity Resilience"; "Low EF - Delayed-Onset Severe Obesity"; and "Low EF - Early-Onset Severe Obesity." Youth in the low-EF, early-onset class displayed higher birth weight and BMI at 6 months, whereas the low-EF, delayed-onset class had rapid weight gain during infancy, parents with class II obesity, and greater cumulative risk and was more likely to be Black and female. CONCLUSIONS:Despite increased obesity risk among this sample, the majority of youth exhibited higher EF and some degree of obesity resilience. Youth with EF deficits displayed the greatest risk for severe obesity but had differing BMI trajectories and obesity risk profiles, which has implications for obesity intervention.
PMID: 33369183
ISSN: 1930-739x
CID: 4747492
When Less is Not More: Population-level Perspective on Adnexal Cyst Surveillance for Post-Menopausal Women
Kang, Stella K; Maturen, Kate E
PMID: 33541553
ISSN: 1558-349x
CID: 4807462
Implementation of Telemental Health (TMH) psychological services for rural veterans at the VA New York Harbor Healthcare System
Chen, Cory K; Palfrey, Amy; Shreck, Erica; Silvestri, Brittney; Wash, Lauren; Nehrig, Nicole; Baer, Alyssa L; Schneider, Jennifer A; Ashkenazi, Sagiv; Sherman, Scott E; Chodosh, Joshua
Meeting the mental health needs of our current veteran population is one of the primary challenges facing the Veteran's Health Administration (VHA). Particularly for veterans residing in rural areas, the lack of providers, high provider turnover, and the burden of traveling long distances to VHA facilities may contribute to difficulties accessing mental health care. Telemental Health (TMH) services help bridge the geographic gap between mental health providers and veterans who need mental health services. The VHA TMH Hub initiative has attempted to leverage changes in technology-facilitated care by developing a model in which a facility "hub" could expand mental health resources to remote "spoke" clinics and veterans' residences. This paper describes the implementation of the VA New York Harbor Health care System (VA NYH) TMH Hub, which was one of 6 programs funded by the VHA Office of Rural Health (ORH) in September 2016. We will describe the structure of the program, services provided, veterans served, and our efforts to integrate quality improvement, research, and clinical training into the operations of the program. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
PMID: 30742470
ISSN: 1939-148x
CID: 3684642
Subgroup Variation and Neighborhood Social Gradients-an Analysis of Hypertension and Diabetes Among Asian Patients (New York City, 2014-2017)
Feldman, Justin M; Conderino, Sarah; Islam, Nadia S; Thorpe, Lorna E
Diabetes and hypertension are socially patterned by individual race/ethnicity and by neighborhood economic context, but distributions among Asian subgroups are undercharacterized. We examined variation in prevalence for both conditions, comparing between US Asian subgroups, including within South Asian nationalities, and comparing within subgroups by neighborhood economic context. We obtained data on a non-probability sample of 633,664 patients ages 18-64 in New York City, NY, USA (2014-2017); 30,138 belonged to one of seven Asian subgroups (Asian Indian, Bangladeshi, Pakistani, Chinese, Korean, Japanese, and Filipino). We used electronic health records to classify disease status. We characterized census tract economic context using the Index of Concentration at the Extremes and estimated prevalence differences using multilevel models. Among Asian men, hypertension prevalence was highest for Filipinos. Among Asian women, hypertension prevalence was highest for Filipinas and Bangladeshis. Diabetes prevalence was highest among Pakistanis and Bangladeshis of both genders, exceeding all other Asian and non-Asian groups. There was consistent evidence of an economic gradient for both conditions, whereby persons residing in the most privileged neighborhood tertile had the lowest disease prevalence. The economic gradient was particularly strong for diabetes among Pakistanis, whose prevalence in the most deprived tertile exceeded that of the most privileged by 9 percentage points (95% CI 3, 14). Only Koreans departed from the trend, experiencing the highest diabetes prevalence in the most privileged tertile. US Asian subgroups largely demonstrate similar neighborhood economic gradients as other groups. Disaggregating Asian subgroups, including within South Asian nationalities, reveals important heterogeneity in prevalence.
PMID: 32488823
ISSN: 2196-8837
CID: 4514682
Virtual Urgent Care Quality and Safety in the Time of Coronavirus
Smith, Silas W; Tiu, Janelle; Caspers, Christopher G; Lakdawala, Viraj S; Koziatek, Christian A; Swartz, Jordan L; Lee, David C; Jamin, Catherine T; Femia, Robert J; Haines, Elizabeth J
BACKGROUND:Telemedicine use rapidly increased during the COVID-19 pandemic. This study assessed quality aspects of rapid expansion of a virtual urgent care (VUC) telehealth system and the effects of a secondary telephonic screening initiative during the pandemic. METHODS:A retrospective cohort analysis was performed in a single health care network of VUC patients from March 1, 2020, through April 20, 2020. Researchers abstracted demographic data, comorbidities, VUC return visits, emergency department (ED) referrals and ED visits, dispositions, intubations, and deaths. The team also reviewed incomplete visits. For comparison, the study evaluated outcomes of non-admission dispositions from the ED: return visits with and without admission and deaths. We separately analyzed the effects of enhanced callback system targeting higher-risk patients with COVID-like illness during the last two weeks of the study period. RESULTS:A total of 18,278 unique adult patients completed 22,413 VUC visits. Separately, 718 patient-scheduled visits were incomplete; the majority were no-shows. The study found that 50.9% of all patients and 74.1% of patients aged 60 years or older had comorbidities. Of VUC visits, 6.8% had a subsequent VUC encounter within 72 hours; 1.8% had a subsequent ED visit. Of patients with enhanced follow-up, 4.3% were referred for ED evaluation. Mortality was 0.20% overall; 0.21% initially and 0.16% with enhanced follow-up (p = 0.59). Males and black patients were significantly overrepresented in decedents. CONCLUSION/CONCLUSIONS:Appropriately deployed VUC services can provide a pragmatic strategy to care for large numbers of patients. Ongoing surveillance of operational, technical, and clinical factors is critical for patient quality and safety with this modality.
PMCID:7566682
PMID: 33358323
ISSN: 1938-131x
CID: 4731212
Urine Metabolites Associated with the Dietary Approaches to Stop Hypertension (DASH) Diet: Results from the DASH-Sodium Trial
Kim, Hyunju; Lichtenstein, Alice H; Wong, Kari E; Appel, Lawrence J; Coresh, Josef; Rebholz, Casey M
SCOPE:Serum metabolomic markers of the Dietary Approaches to Stop Hypertension (DASH) diet are previously reported. In an independent study, the similarity of urine metabolomic markers are investigated. METHODS AND RESULTS:In the DASH-Sodium trial, participants are randomly assigned to the DASH diet or control diet, and received three sodium interventions (high, intermediate, low) within each randomized diet group in random order for 30 days each. Urine samples are collected at the end of each intervention period and analyzed for 938 metabolites. Two comparisons are conducted: 1) DASH-high sodium (n = 199) versus control-high sodium (n = 193), and 2) DASH-low sodium (n = 196) versus control-high sodium. Significant metabolites identified using multivariable linear regression are compared and the top 10 influential metabolites identified using partial least-squares discriminant analysis to the results from the DASH trial. Nine out of 10 predictive metabolites of the DASH-high sodium and DASH-low sodium diets are identical. Most candidate biomarkers from the DASH trial replicated. N-methylproline, chiro-inositol, stachydrine, and theobromine replicated as influential metabolites of DASH diets. CONCLUSIONS:Candidate biomarkers of the DASH diet identified in serum replicated in urine. Replicated influential metabolites are likely to be objective biomarkers of the DASH diet.
PMCID:7967699
PMID: 33300290
ISSN: 1613-4133
CID: 5585972
The Effects of Four Doses of Vitamin D Supplements on Falls in Older Adults : A Response-Adaptive, Randomized Clinical Trial
Appel, Lawrence J; Michos, Erin D; Mitchell, Christine M; Blackford, Amanda L; Sternberg, Alice L; Miller, Edgar R; Juraschek, Stephen P; Schrack, Jennifer A; Szanton, Sarah L; Charleston, Jeanne; Minotti, Melissa; Baksh, Sheriza N; Christenson, Robert H; Coresh, Josef; Drye, Lea T; Guralnik, Jack M; Kalyani, Rita R; Plante, Timothy B; Shade, David M; Roth, David L; Tonascia, James; ,
BACKGROUND:Vitamin D supplementation may prevent falls in older persons, but evidence is inconsistent, possibly because of dosage differences. OBJECTIVE:supplements on falls. DESIGN:2-stage Bayesian, response-adaptive, randomized trial. (ClinicalTrials.gov: NCT02166333). SETTING:2 community-based research units. PARTICIPANTS:688 participants, aged 70 years and older, with elevated fall risk and a serum 25-hydroxyvitamin D [25-(OH)D] level of 25 to 72.5 nmol/L. INTERVENTION:doses, and the best noncontrol dose for preventing falls was determined. After dose finding, participants previously assigned to receive noncontrol doses received the best dose, and new enrollees were randomly assigned to receive 200 IU/d or the best dose. MEASUREMENTS:Time to first fall or death over 2 years (primary outcome). RESULTS: = 0.54). Analysis of falls with adverse outcomes suggested greater risk in the experience-with-best-dose group versus the 200-IU/d group (serious fall: HR, 1.87 [CI, 1.03 to 3.41]; fall with hospitalization: HR, 2.48 [CI, 1.13 to 5.46]). LIMITATIONS:per day, not a placebo. Dose finding ended before the prespecified thresholds for dose suspension and dose selection were reached. CONCLUSION:doses of 1000 IU/d or higher. PRIMARY FUNDING SOURCE:National Institute on Aging.
PMID: 33284677
ISSN: 1539-3704
CID: 5585962